News & Events
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reports first quarter 2025 financial results and provided a business update on May 8, 2025 at 4:30PM ET.
READ MORECrinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 124,950 shares of its common stock and an aggregate of 84,725 restricted stock unit awards to 26 new non-executive employees.
READ MORECrinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
Crinetics announces European Medicines Agency Validation of Marketing Authorization Application and Orphan Drug Designation for paltusotine in acromegaly.
READ MORECrinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 95,675 shares of its common stock to fifteen new non-executive employees and 80,000 to one new executive employee.
READ MORECrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update.
READ MORECrinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
Crinetics company announces the appointment of Tobin Schilke as chief financial officer, effective February 28, 2025.
READ MORECrinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
Crinetics' company management will participate in the TD Cowen 45th Annual Healthcare Conference on March 3, and the Leerink Global Healthcare Conference on March 10.
READ MORECrinetics Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock and granted an aggregate of 9,950 restricted stock unit awards to 14 new non-executive employees.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
